Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

September 19, 2018

Study Examines Erleada Add-on for Non-metastatic Castration-resistant Prostate Cancer

News

Patients with castration-resistant prostate cancer (CRPC) who are at high risk for developing metastasis may safely add Erleada (apalutamide) to androgen deprivation therapy without worrying about their quality of life, ... Read more

May 19, 2017

Advanced Prostate Cancer Patients Do Not Benefit from Reolysin, Taxotere Combo, Trial Shows

News

Patients with metastatic castration-resistant prostate cancer do not benefit from the addition of Reolysin (pelareorep) to Taxotere (docetaxel), according to recent data from a Phase 2 trial. The trial (NCT01619813) failed to ... Read more

May 17, 2017May 17, 2017

Blocking Aggressive Prostate Cancer’s Fat-burning Mechanism Overcomes Disease’s Resistance to Xtandi

News

A major problem treating an aggressive form of prostate cancer is that it develops resistance to the androgen therapies used to combat it. One solution could be targeting the ... Read more

April 21, 2017April 21, 2017

BXCL701, Immune Checkpoint Inhibitors Combo Holds Promise for Castration-resistant Prostate Cancer Patients

News

Combining BioXcel‘s BXCL701 with immune checkpoint inhibitors may potentially help treat men with castration-resistant prostate cancer (CRPC), says the Branford, Conn., pharma company. Dr. Luca Rastelli, BioXCel’s vice-president for oncology ... Read more

April 3, 2017

Researchers Working on Alternative to Biopsy as Way to Diagnose Prostate Cancer

News

Washington State University researchers have developed a new way to capture cancer-derived particles called exosomes from prostate cancer, a finding that could offer an alternative to the invasive approach ... Read more

March 29, 2017March 29, 2017

Study of MVI-118 Prostate Cancer Vaccine Expands, Adding Site in Seattle

News

A Phase 1 study evaluating the MVI-118 cancer vaccine in patients with metastatic prostate cancer is expanding to a third clinical site, the University of Washington in Seattle. The ... Read more

March 28, 2017March 28, 2017

Pathway Controlling Cytoskeleton Plays Key Role in Spread of Prostate Cancer, U.K. Study Finds

News

The cytoskeleton, a dynamic set of filaments that controls the shape of cells, plays a key function in the spread of prostate cancer cells to distant organs to establish metastasis, according ... Read more

March 22, 2017

Endostatin May Be Key to Preventing Prostate Cancer from Progressing to Worse Form

News

A naturally occurring substance called endostatin may be the key to preventing prostate cancer from progressing to castration-resistant prostate cancer (CRPC), an advanced stage of the disease in which ... Read more

March 21, 2017March 21, 2017

Compressing 8-Week Radiation Therapy into 4 Weeks Just as Effective in Treating Localized Prostate Cancer

News

Four weeks of radiation therapy at larger doses has the same effect as conventional radiation therapy administered to prostate cancer patients over eight weeks, according to results from a Phase ... Read more

March 17, 2017March 17, 2017

Immunotherapy Combo Effective in Castration-resistant Prostate Cancer Mouse Models, Study Finds

News

Combining immune checkpoint inhibitors with drugs that target a population of myeloid-derived suppressor cells (MDSCs) may offer hope for men with metastatic prostate cancer who no longer respond to androgen deprivation therapy ... Read more